Open Access<p>Monocentric Analysis of the Effectiveness and Financial Consequences of the Use of Lenograstim versus Filgrastim for Mobilization of Peripheral Blood Progenitor Cells in Patients with Lymphoma and Myeloma Receiving Chemotherapy and Autologous Stem Cell Transplantation</p>
Author(s) -
Umberto Restelli,
Davide Croce,
Erminio Bonizzoni,
M. Marzanatti,
Angelo Andreini,
Marco Sorio,
Cristina Tecchio,
Erika Barison,
Fabio Benedetti
Publication year - 2020
Publication title -
journal of blood medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.676
H-Index - 18
ISSN - 1179-2736
DOI - 10.2147/jbm.s224173
Subject(s) - filgrastim , medicine , biosimilar , granulocyte colony stimulating factor , cd34 , hematopoietic stem cell transplantation , autologous stem cell transplantation , apheresis , multiple myeloma , oncology , surgery , stem cell , transplantation , chemotherapy , platelet , biology , genetics
Granulocyte-colony stimulating factors (G-CSFs) are widely used to mobilize CD34 + stem cells and to support the engraftment after hematopoietic stem cell transplantation (HSCT). A budget impact analysis and an incremental cost-effectiveness study of two G-CSFs (Lenograstim and Filgrastim biosimilar), considering engraftment, number of hospitalization days and number of G-CSF vials administered were performed.